# Two Peptides. One Standard: What The Record Shows. > Peptide Baddies — Skin & Aesthetics Research Peptides — Peptide Baddies reviews Skin & Aesthetics research peptides — Melanotan II and GLOW — candidly. Cited findings, labeled anecdote, and the safety record in full, including the melanoma signal. **SKIN & AESTHETICS RESEARCH** Melanotan II and GLOW, read candidly — mechanism, findings, and the safety signal the marketing skips. ### [Melanotan II](/melanotan-2) A melanocortin peptide that darkens skin without sun. Also raises libido and suppresses appetite. Case reports link it to new moles, kidney injury, and melanoma. ### [GLOW (research blend)](/glow) A three-peptide combination — GHK-Cu, BPC-157, TB-500 — aimed at skin texture and tissue repair. Never tested as a blend in a controlled human trial. ## The short version Peptide Baddies covers two research peptides used off-label for skin, tone, and tanning: **Melanotan II** and **GLOW**, a three-peptide blend. Both are unapproved. Both move through research-chemical markets with no quality control. Both carry safety signals that are documented, not theoretical. Melanotan II darkens skin by switching on a receptor in skin cells that normally responds to sunlight. It also suppresses appetite and raises libido — the same receptor system acting in the brain. The part that gets left out of marketing copy: published case reports link it to new and changing moles, kidney injury, and melanoma [1][3]. GLOW pairs a copper-peptide (GHK-Cu) with two tissue-repair peptides (BPC-157 and TB-500). The rationale is mechanistic — three research programs converging on skin and repair. No study has tested the combination itself in people. This site states what the literature and the community record actually say. Nothing here is for sale. Nothing here is a dose recommendation. ## Aesthetics research, candidly Most sites covering tanning and skin peptides sell the upside and bury the rest. This one does not. Melanotan II has a real efficacy signal — it produces measurable pigmentation without UV exposure, in controlled pilot studies [6]. It also has a real adverse-event literature: renal infarction [3], priapism, posterior reversible encephalopathy syndrome, and case-reported melanoma. Both facts belong on the same page. Neither cancels the other out. GLOW sits in a different evidentiary spot. Its individual components — GHK-Cu, BPC-157, TB-500 — each have their own research base, some of it decades deep [11][12]. The blend itself has none. A 2026 review of unapproved peptide therapies names all three constituents together and is blunt about the gap: favorable outcomes in animal models, scarce human safety data, and a gray market operating largely outside regulatory oversight [8]. Candid, here, means citing the finding and the caution in the same breath, and never dressing a research chemical up as a cosmetic. Neither peptide reviewed on this site is approved for human use by any regulator. ## What are research peptides? Peptides are short chains of amino acids — smaller than a protein, built from the same parts. The compounds covered here are synthetic analogs of naturally occurring signaling molecules. Melanotan II is a lab-modified, cyclic version of alpha-melanocyte-stimulating hormone (alpha-MSH), engineered to resist breakdown and stay active longer than the natural hormone [4]. GHK-Cu is the copper-bound form of a tripeptide already present in human plasma, one that declines with age [11]. BPC-157 and TB-500 are derived from naturally occurring protective proteins and studied mainly in animal models of tissue injury. None of the peptides on this site are approved medicines. They are sold by research suppliers, described as for laboratory use only, and used off-label by people who inject them without medical supervision. That gap — between what a peptide does in a study and what happens when an unregulated version is self-administered — is where most of the real risk on this site lives. ## How to read this site Every compound page follows the same structure: a plain-English opening, what the peptide is, how it works, what the published research found, and then reported effects and safety in full — including community-reported anecdote, clearly labeled as such, and the cited safety-literature cautions. Nothing is softened for either compound. Melanotan II's melanoma and kidney signals are stated on the same page as its tanning efficacy. GLOW's untested-blend status is stated on the same page as its component research. Quantitative claims — percentages, durations, participant counts — carry a bracketed citation number tied to the [references list](/references). Community-reported effects are anecdotal and never come with a dose. Start with [Melanotan II](/melanotan-2), read [GLOW](/glow), or go straight to the [side-by-side comparison](/compare). --- Peptide Baddies is a literature desk on skin and tanning peptides, not a clinic, not a vendor, not a dermatologist.